Self-Administered Autoimmune Injectables


immunotherapeutic drugs devices patient enablement          Published October 2018 •  Catalog no. SJA616F  •  Price US $3,850



 

The advantages of administering immunotherapeutic injectables subcutaneously is now well accepted and has been more-or-less institutionalized in the drug life cycle development process for non-oncology indications. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. The migration to patient self-care presents several areas of concern. By making the patient the single point of failure for dosing adherence and successful drug delivery, devices and protocols must be developed and tested to a new, higher standard. New generation drug injection devices are increasingly being created to address patient adherence issues by making the delivery of injectable drugs less complicated and intimidating

Bar_Graph Self-Administered Autoimmune Injectables Report Brochure (Download PDF)

Blue document  Self-Administered Autoimmune Injectables Report Order Form (Download PDF)

 

  Click HERE to Order Online

 


Self-Administered Autoimmune Injectables – What You Will Learn

•  What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?
•  What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?
•  What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2022?
•  How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
•  What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?
•  What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?


Self-Administered Autoimmune Injectables – Summary of Contents

Executive Summary

Market Dynamics

Competitive Landscape
Drug Supply Chain Activity
Product Design and Enablement Factors
Ease of Use
Patient Adherence
Dosing Frequency
Human Engineering/Ergonomics
Pre- and Post-Marketing Device Evolution

Self-administered Enabling Devices

Device Selection – Stability and Material Issues
Prefilled Syringes
Autoinjectors
Special Feature Autoinjectors
Pen Injectors
Dual Chamber Pens
Emerging Devices

Self-administered Therapeutic Autoimmune Drugs

mAbs
Cytokines
Fusion Proteins

Autoimmune Therapeutics Markets

Ankylosing Spondylitis
Crohn’s Disease
Adult Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Multiple Sclerosis
Psoriatic Arthritis
Ulcerative Colitis

Market Factors

Regulatory Factors
Clinical Trial Protocols & Endpoints
Alliances and Partnerships

Company Profile


Read the Press Release HERE